nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors

References

• FinnOJCancer immunologyN Engl J Med20083582704271518565863
   PubMed Web of Science ®Google Scholar
• AhmadMReesRCAliSAEscape from immunotherapy: possible mechanisms that influence tumor regression/progressionCancer Immunol Immunother20045384485415197495
   PubMed Web of Science ®Google Scholar
• ChenDSMellmanIOncology meets immunology: the cancer-immunity cycleImmunity20133911023890059
   PubMed Web of Science ®Google Scholar
• DisisMLImmune regulation of cancerJ Clin Oncol2010284531453820516428
   PubMed Web of Science ®Google Scholar
• GajewskiTFSchreiberHFuYXInnate and adaptive immune cells in the tumor microenvironmentNat Immunol2013141014102224048123
   PubMed Web of Science ®Google Scholar
• MellmanICoukosGDranoffGCancer immunotherapy comes of ageNature201148048048922193102
   PubMed Web of Science ®Google Scholar
• BlankCMackensenAContribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasionCancer Immunol Immunother20075673974517195077
   PubMed Web of Science ®Google Scholar
• AllardBTurcotteMStaggJCD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growthJ Biomed Biotechnol2012201248515623125525
   PubMedGoogle Scholar
• GalonJCostesASanchez-CaboFType, density, and location of immune cells within human colorectal tumors predict clinical outcomeScience20063131960196417008531
   PubMed Web of Science ®Google Scholar
• KreikeBvan KouwenhoveMHorlingsHGene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomasBreast Cancer Res20079R6517910759
   PubMed Web of Science ®Google Scholar
• Dieu-NosjeanMCAntoineMDanelCLong-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structuresJ Clin Oncol2008264410441718802153
   PubMed Web of Science ®Google Scholar
• ZhangLConejo-GarciaJRKatsarosDIntratumoral T cells, recurrence, and survival in epithelial ovarian cancerN Engl J Med200334820321312529460
   PubMed Web of Science ®Google Scholar
• Ene-ObongAClearAJWattJActivated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinomaGastroenterology20131451121113223891972
   PubMed Web of Science ®Google Scholar
• MahmoudSMPaishECPoweDGTumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancerJ Clin Oncol2011291949195521483002
   PubMed Web of Science ®Google Scholar
• CurielTJCoukosGZouLSpecific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survivalNat Med20041094294915322536
   PubMed Web of Science ®Google Scholar
• GobertMTreilleuxIBendriss-VermareNRegulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcomeCancer Res2009692000200919244125
   PubMed Web of Science ®Google Scholar
• HasegawaTSuzukiHYamauraTPrognostic value of peripheral and local forkhead box P3 regulatory T cells in patients with non-small-cell lung cancerMol Clin Oncol2014268569425054031
   PubMedGoogle Scholar
• TangYXuXGuoSAn increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinomaPLoS One20149e9155124637664
   PubMed Web of Science ®Google Scholar
• RibasATumor immunotherapy directed at PD-1N Engl J Med20123662517251922658126
   PubMed Web of Science ®Google Scholar
• McDermottDFAtkinsMBPD-1 as a potential target in cancer therapyCancer Med2013266267324403232
   PubMed Web of Science ®Google Scholar
• Opdivo (nivolumab) injection, for intravenous use [package insert]New YorkBristol-Myers Squibb2016
   Google Scholar
• Yervoy (ipilimumab) injection, for intravenous use [package insert]New YorkBristol-Myers Squibb2015
   Google Scholar
• Keytruda (pembrolizumab) for injection, for intravenous use [package insert]Whitehouse Station, NJMerck & Co Inc2016
   Google Scholar
• Tecentriq (atezolizumab) injection, for intravenous use [package insert]BaselHoffman-La Roche Ltd2016
   Google Scholar
• Yervoy (ipilimumab) [summary of product characteristics]New YorkBristol-Myers Squibb2015
   Google Scholar
• Keytruda (pembrolizumab) [summary of product characteristics]Whitehouse Station, NJMerck & Co Inc2016
   Google Scholar
• AstraZenecaDurvalumab granted breakthrough therapy designation by US FDA for treatment of patients with PD-L1 positive urothelial bladder cancer [press release]LondonAstraZeneca2016 [February 17]. Available from: https://www.astrazeneca.com/media-centre/press-releases/2016/Durvalumab-granted-Breakthrough-Therapy-designation-by-US-FDA-for-treatment-of-patients-with-PD-L1-positive-urothelial-bladder-cancer-17022016.htmlAccessed March 8, 2016
   Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med201036371172320525992
   PubMed Web of Science ®Google Scholar
• RobertCLongGVBradyBNivolumab in previously untreated melanoma without BRAF mutationN Engl J Med201537232033025399552
   PubMed Web of Science ®Google Scholar
• RobertCSchachterJLongGVPembrolizumab versus ipilimumab in advanced melanomaN Engl J Med20153722521253225891173
   PubMed Web of Science ®Google Scholar
• RibasAPuzanovIDummerRPembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialLancet Oncol20151690891826115796
   PubMed Web of Science ®Google Scholar
• Opdivo (nivolumab)TokyoOno Pharmaceutical Co Ltd2014
   Google Scholar
• Opdivo (nivolumab) [summary of product characteristics]New YorkBristol-Myers Squibb2016
   Google Scholar
• LarkinJHodiFSWolchokJDCombined nivolumab and ipilimumab or monotherapy in untreated melanomaN Engl J Med201537312701271
   PubMed Web of Science ®Google Scholar
• BorghaeiHPaz-AresLHornLNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancerN Engl J Med20153731627163926412456
   PubMed Web of Science ®Google Scholar
• BrahmerJReckampKLBaasPNivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancerN Engl J Med201537312313526028407
   PubMed Web of Science ®Google Scholar
• HamanishiJMandaiMIkedaTDurable tumor remission in patients with platinum-resistant ovarian cancer receiving nivolumabJ Clin Oncol2015335570
   Google Scholar
• LeDTBendellJCCalvoESafety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): results from the CheckMate-032 studyJ Clin Oncol201634626578608
   PubMedGoogle Scholar
• PlimackERHammersHJRiniBIUpdated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC)J Clin Oncol2015334553
   Google Scholar
• MotzerRJEscudierBMcDermottDFNivolumab versus everolimus in advanced renal-cell carcinomaN Engl J Med20153731803181326406148
   PubMed Web of Science ®Google Scholar
• HerbstRSBaasPKimDWPembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trialLancet20163871540155026712084
   PubMed Web of Science ®Google Scholar
• LutzkyJAntoniaSJBlake-HaskinsAA phase 1 study of MEDI4736, an anti-PD-L1 antibody, in patients with advanced solid tumorsJ Clin Oncol2014323001
   Google Scholar
• WinogradRByrneKTEvansRAInduction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinomaCancer Immunol Res2015339941125678581
   PubMed Web of Science ®Google Scholar
• RoyalRELevyCTurnerKPhase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinomaJ Immunother20103382883320842054
   PubMed Web of Science ®Google Scholar
• BrahmerJRTykodiSSChowLQSafety and activity of anti-PD-L1 antibody in patients with advanced cancerN Engl J Med20123662455246522658128
   PubMed Web of Science ®Google Scholar
• ZitvogelLGalluzziLSmythMJKroemerGMechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillanceImmunity201339748823890065
   PubMed Web of Science ®Google Scholar
• KaufmanHLKirkwoodJMHodiFSThe Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanomaNat Rev Clin Oncol20131058859823982524
   PubMed Web of Science ®Google Scholar
• BracciLSchiavoniGSistiguABelardelliFImmune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancerCell Death Differ201421152523787994
   PubMed Web of Science ®Google Scholar
• FridmanWHPagesFSautes-FridmanCGalonJThe immune contexture in human tumours: impact on clinical outcomeNat Rev Cancer20121229830622419253
   PubMed Web of Science ®Google Scholar
• EmensLAReillyRTJaffeeEMBreast cancer vaccines: maximizing cancer treatment by tapping into host immunityEndocr Relat Cancer20051211715788636
   PubMed Web of Science ®Google Scholar
• MachielsJPReillyRTEmensLACyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized miceCancer Res2001613689369711325840
   PubMed Web of Science ®Google Scholar
• LutsiakMESemnaniRTDe PascalisRKashmiriSVSchlomJSabzevariHInhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamideBlood20051052862286815591121
   PubMed Web of Science ®Google Scholar
• ChangCLHsuYTWuCCDose-dense chemotherapy improves mechanisms of antitumor immune responseCancer Res20137311912723108141
   PubMed Web of Science ®Google Scholar
• EmensLAAsquithJMLeathermanJMTimed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activationJ Clin Oncol2009275911591819805669
   PubMed Web of Science ®Google Scholar
• Abraxane for injectable suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) [package insert]Summit, NJCelgene Corporation2015
   Google Scholar
• Taxotere (docetaxel) [package insert]Bridgewater, NJSanofi2013
   Google Scholar
• Taxol (paclitaxel) [package insert]New YorkBristol-Myers Squibb2011
   Google Scholar
• ChanOTYangLXThe immunological effects of taxanesCancer Immunol Immunother20004918118510941900
   PubMed Web of Science ®Google Scholar
• DemariaSVolmMDShapiroRLDevelopment of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapyClin Cancer Res200173025303011595690
   PubMed Web of Science ®Google Scholar
• CarsonWE3rdShapiroCLCrespinTRThorntonLMAndersenBLCellular immunity in breast cancer patients completing taxane treatmentClin Cancer Res2004103401340915161695
   PubMed Web of Science ®Google Scholar
• DenkertCLoiblSNoskeATumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancerJ Clin Oncol20102810511319917869
   PubMed Web of Science ®Google Scholar
• TsudaNChangDZMineTTaxol increases the amount and T cell activating ability of self-immune stimulatory multimolecular complexes found in ovarian cancer cellsCancer Res2007678378838717804754
   PubMed Web of Science ®Google Scholar
• VicariAPLuuRZhangNPaclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouseCancer Immunol Immunother20095861562818802696
   PubMed Web of Science ®Google Scholar
• GarnettCTSchlomJHodgeJWCombination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancementClin Cancer Res2008143536354418519787
   PubMed Web of Science ®Google Scholar
• MichelsTShurinGVNaiditchHSevkoAUmanskyVShurinMRPaclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent mannerJ Immunotoxicol2012929230022283566
   PubMed Web of Science ®Google Scholar
• TsavarisNKosmasCVadiakaMKanelopoulosPBoulamatsisDImmune changes in patients with advanced breast cancer undergoing chemotherapy with taxanesBr J Cancer200287212712085250
   PubMed Web of Science ®Google Scholar
• SevkoAMichelsTVrohlingsMAnti-tumor effect of paclitaxel is mediated by inhibition of MDSCs and chronic inflammation in the spontaneous melanoma modelJ Immunol20131902464247123359505
   PubMed Web of Science ®Google Scholar
• MullinsDMartinsRSBurgerCJElgertKDTumor cell-derived TGF-β and IL-10 dysregulate paclitaxel-induced macrophage activationJ Leukoc Biol20016912913711200057
   PubMedGoogle Scholar
• LynchTJBondarenkoILuftAIpilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II studyJ Clin Oncol2012302046205422547592
   PubMed Web of Science ®Google Scholar
• HorinouchiHYamamotoNFujiwaraYPhase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancerInvest New Drugs20153388188925924991
   PubMed Web of Science ®Google Scholar
• ReckMBondarenkoILuftAIpilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trialAnn Oncol201324758322858559
   PubMed Web of Science ®Google Scholar
• WeberJHamidOAminARandomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanomaCancer Immun201313723833564
   PubMedGoogle Scholar
• JamalRBelangerKFriedmannJRandomized phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM)J Clin Oncol2014329066
   Google Scholar
• JamalRL KempenLThebaultPOne-year overall survival (OS) and biomarker correlates from a phase II study of ipilimumab (IPI) with carboplatin and paclitaxel (CP) in patients with unresectable stage III or IV metastatic melanoma (MM)J Clin Oncol2015339062
   Google Scholar
• AntoniaSBrahmerJGettingerSNivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC)J Clin Oncol2014328113
   Web of Science ®Google Scholar
• GadgeelSStevensonJLangerCPembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-CJ Clin Oncol2016349016
   Web of Science ®Google Scholar
• GardnerERDahutWLScriptureCDRandomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxelClin Cancer Res2008144200420518594000
   PubMed Web of Science ®Google Scholar
• DesaiNTrieuVYaoZIncreased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxelClin Cancer Res2006121317132416489089
   PubMed Web of Science ®Google Scholar
• ChenNLiYYeYPalmisanoMChopraRZhouSPharmacokinetics and pharmacodynamics of nab-paclitaxel in patients with solid tumors: disposition kinetics and pharmacology distinct from solvent-based paclitaxelJ Clin Pharmacol2014541097110724719309
   PubMed Web of Science ®Google Scholar
• GradisharWJTjulandinSDavidsonNPhase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancerJ Clin Oncol2005237794780316172456
   PubMed Web of Science ®Google Scholar
• SocinskiMABondarenkoIKarasevaNAWeekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trialJ Clin Oncol2012302055206222547591
   PubMed Web of Science ®Google Scholar
• Von HoffDDErvinTArenaFPIncreased survival in pancreatic cancer with nab-paclitaxel plus gemcitabineN Engl J Med20133691691170324131140
   PubMed Web of Science ®Google Scholar
• CamidgeDRLiuSVPowderlyJAtezolizumab (MPDL3280A) combined with platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a phase IB safety and efficacy updateJ Thorac Oncol201510S176S177
   Google Scholar
• GiacconeGCamidgeDRLiuSVSafety, activity and biomarker of atezolizumab (MPDL3280A) with platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): a phase IB studyEur J Cancer201551S107S108
   Web of Science ®Google Scholar
• AdamsSDiamondJHamiltonEPhase IB trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC)J Clin Oncol2016341009
   Google Scholar
• ClinicalTrials.gov [website on the Internet] Available from: http://www.clinicaltrials.govAccessed January 21, 2016
   Google Scholar
• LeDTLutzEUramJNEvaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancerJ Immunother20133638238923924790
   PubMed Web of Science ®Google Scholar
• National Immunotherapy CoalitionCancer MoonShot 2020 Available from: http://www.cancermoonshot2020.orgAccessed April 4, 2016
   Google Scholar